A decade ago, most of the advanced cardiac devices used in Indian cath labs came from the same handful of American and European manufacturers, at prices that put them well out of reach for the majority of India’s cardiac patients. That picture has genuinely shifted. India now has homegrown devices competing on clinical outcomes with global market leaders, in categories ranging from coronary stents to artificial heart valves, alongside categories where India still depends almost entirely on imports. Here’s an honest look at where the country’s next-generation cardiac device landscape actually stands, across five key categories.
1. TAVR/TAVI: India’s Genuine Success Story
Transcatheter Aortic Valve Replacement (TAVR, also called TAVI) lets doctors replace a diseased aortic valve through a catheter inserted via the femoral artery, avoiding open-heart surgery entirely, a genuinely transformative option for elderly or high-surgical-risk patients with severe aortic stenosis.
This is arguably India’s clearest cardiac device success story. Meril Life Sciences launched Myval in 2018, becoming the first Indian company to commercialise TAVR technology domestically, designed, developed, and manufactured entirely in India by a team of roughly 150 Meril engineers, including the valve itself (built from bovine and porcine pericardial tissue on a nickel-cobalt alloy frame) and the full balloon-delivery and accessory ecosystem around it. Myval wasn’t a “good enough for India” alternative, either: the LANDMARK trial, presented at EuroPCR 2024, found the balloon-expandable Myval valve non-inferior to Medtronic’s self-expanding Evolut and Edwards Lifesciences‘ balloon-expandable Sapien 3 systems, the two dominant global TAVR platforms, on short-term outcomes. Myval has since gone on to earn CE marking in Europe and a distribution partnership with Japan Lifeline for the Japanese market, a genuine India-to-world technology export.
2. New-Generation Coronary Stents: From Domestic Staple to Export Leader
Drug-eluting coronary stents remain the most widely used cardiac device category in India by sheer procedure volume, and this is also where Indian manufacturing has the longest track record. Sahajanand Medical Technologies (SMT) holds a genuinely important global first: SMT was the first company in the world to receive CE certification for a drug-eluting stent with a biodegradable polymer, a coating that dissolves over time rather than remaining permanently in the artery, an advance associated with reduced long-term inflammation risk compared to older durable-polymer stents.
The current generation of that technology, Supraflex Cruz, has spent 2026 building a genuinely international regulatory footprint: the sirolimus-eluting stent recently cleared Health Canada’s Class IV device licence, the highest-risk device tier Health Canada regulates, and separately secured approval from Egypt’s Drug Authority, extending SMT’s stent business into both North America and Africa within the same year. That pattern, an Indian-designed stent clearing high-scrutiny international regulators rather than only competing domestically on price, reflects a broader shift in how Indian cardiac device manufacturing is positioning itself globally.
3. Structural Heart Devices: Moving Beyond the Aortic Valve
“Structural heart” is the broader device category covering catheter-based repair of the heart’s physical architecture, valves, chambers, and the walls and appendages between them, beyond the aortic valve alone. This is the fastest-growing sub-segment within India’s cardiovascular devices market, and it’s where the next wave of Indian device innovation is concentrated.
Meril’s MyClip, an indigenously developed device for mitral valve repair using the transcatheter edge-to-edge repair (TEER) technique, represents India’s entry into this harder structural heart category. TEER devices work by clipping together the leaflets of a leaking mitral valve through a catheter, reducing regurgitation without open-heart surgery, a procedure category that has historically been dominated globally by Abbott’s MitraClip. An indigenously developed Indian alternative in this space follows the same playbook that made Myval successful in aortic valves: domestic engineering capability applied to a device category previously entirely reliant on imports.
4. Heart Valves: Aortic Progress, Mitral and Tricuspid Still Emerging
Looking specifically at valve replacement and repair technology as its own category, India’s progress has been genuinely uneven across valve types, a nuance worth understanding rather than glossing over. Aortic valve replacement, through Myval, is a mature, internationally validated Indian technology. Mitral valve repair, through MyClip, is a newer but genuine indigenous entry. Tricuspid valve intervention, described in the global cardiology literature as the “forgotten” valve until relatively recently, now an active area of transcatheter innovation worldwide, remains considerably earlier-stage globally, and India-specific indigenous tricuspid technology has not reached the same commercial maturity as the aortic and mitral categories.
This uneven progress mirrors exactly the pattern the broader cardiovascular devices market is showing: Indian manufacturers moving fastest in the categories where they got an early, well-resourced start, with harder, more recently-developed procedure categories still catching up.
5. Left Atrial Appendage Closure Devices: India’s Honest Import Gap
Left atrial appendage closure (LAAC) devices offer a genuinely important alternative to lifelong blood-thinning medication for atrial fibrillation patients at high stroke risk, sealing off the small pouch in the heart’s left atrium where roughly 20–30% of AF-related strokes originate as blood clots. It’s also been specifically flagged as the fastest-growing structural heart device sub-segment in India.
Here’s the honest gap in India’s cardiac device landscape: unlike TAVR and coronary stents, LAAC in India remains dominated by imported devices, principally Boston Scientific’s Watchman, Abbott’s Amplatzer Amulet, and Lifetech Scientific’s LAmbre (developed in China). All three have solid, comparable clinical data behind them internationally, with similarly high implant success rates and low peri-procedural complication rates across comparative studies. But none of them represent Indian-developed technology, making LAAC a clear illustration of where India’s structural heart device manufacturing ambition still has genuine ground to cover, a natural next target for the same kind of indigenous development that produced Myval and MyClip.
What This Landscape Tells Us About Indian Cardiac MedTech
Looking across all five categories together, a consistent pattern emerges: India’s cardiac device manufacturing has moved fastest and furthest in categories where a determined domestic player invested early and built genuine engineering depth, Meril in TAVR and mitral repair, SMT in coronary stents. Categories without that early, focused domestic investment, like LAAC, remain import-dependent, regardless of how large or fast-growing the underlying clinical opportunity is.
That’s a useful lesson for where Indian cardiac MedTech goes next. The same combination that produced Myval’s global competitiveness, sustained R&D investment, a clear regulatory pathway through CDSCO, and international clinical validation through trials like LANDMARK, is a repeatable template, not a one-off success. Whether an Indian manufacturer applies that same playbook to left atrial appendage closure, tricuspid valve intervention, or the next structural heart category to mature globally will likely determine how much of India’s fast-growing cardiovascular devices market, projected to nearly double by the early 2030s, ends up manufactured domestically, versus continuing to depend on the same handful of American, European, and Chinese device makers that have historically dominated the space.
References
- Wikipedia — Meril Life Sciences (https://en.wikipedia.org/wiki/Meril_Life_Sciences)
- Cardiovascular Business — Myval TAVR Valve Noninferior to Similar Devices From Medtronic, Edwards After 30 Days (https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/tavr/myval-tavr-valve-noninferior-similar-devices-medtronic-edwards-after-30-days)
- Cardiovascular News — Myval: India’s TAVI Technology Is Now Going Global (https://cardiovascularnews.com/myval-indias-tavi-technology-is-now-going-global/)
- MassDevice — Meril Life Sciences Wins Approval for TAVR in India (https://www.massdevice.com/meril-life-sciences-wins-approval-for-tavr-in-india/)
- Business Standard — Sahajanand Medical Technologies Secures Regulatory Approval in Egypt for Supraflex Cruz Coronary Stent (https://www.business-standard.com/content/press-releases-ani/sahajanand-medical-technologies-secures-regulatory-approval-in-egypt-for-supraflex-cruz-coronary-stent-126091600554_1.html)
- Journal of Cardiology — Left Atrial Appendage Occlusion Using LAmbre, Amulet and Watchman in Atrial Fibrillation (https://www.journal-of-cardiology.com/article/S0914-5087(18)30357-5/fulltext)
- PMC / National Library of Medicine — The WATCHMAN Device Is a Promising Solution for Stroke Prevention in Non-Valvular Atrial Fibrillation: Challenges and Future Directions in South and Southeast Asia (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182756/)
- Methodist DeBakey Cardiovascular Journal — The Current and Future Landscape of Structural Heart Interventions (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198246/)
Note: This article reflects publicly available information on device approvals, clinical trial data, and market positioning as of September 2026. Device availability, indications, and regulatory status should be confirmed with treating cardiologists, as clinical suitability varies by individual patient anatomy and risk profile.